Notice: This company has been marked as potentially delisted and may not be actively trading. GX Acquisition (GXGX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends GXGX vs. MBX, PGEN, OLMA, CRVS, CTNM, CMRX, LFVN, XOMA, TNGX, and TRVIShould you be buying GX Acquisition stock or one of its competitors? The main competitors of GX Acquisition include MBX Biosciences (MBX), Precigen (PGEN), Olema Pharmaceuticals (OLMA), Corvus Pharmaceuticals (CRVS), Contineum Therapeutics (CTNM), Chimerix (CMRX), LifeVantage (LFVN), XOMA (XOMA), Tango Therapeutics (TNGX), and Trevi Therapeutics (TRVI). These companies are all part of the "medical" sector. GX Acquisition vs. MBX Biosciences Precigen Olema Pharmaceuticals Corvus Pharmaceuticals Contineum Therapeutics Chimerix LifeVantage XOMA Tango Therapeutics Trevi Therapeutics MBX Biosciences (NYSE:MBX) and GX Acquisition (NASDAQ:GXGX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, community ranking, institutional ownership and valuation. Does the MarketBeat Community favor MBX or GXGX? MBX Biosciences received 2 more outperform votes than GX Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformMBX BiosciencesOutperform Votes4100.00% Underperform VotesNo VotesGX AcquisitionOutperform Votes2100.00% Underperform VotesNo Votes Is MBX or GXGX more profitable? MBX Biosciences' return on equity of 0.00% beat GX Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets MBX BiosciencesN/A N/A N/A GX Acquisition N/A -985.20%-6.02% Which has preferable earnings & valuation, MBX or GXGX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMBX BiosciencesN/AN/AN/AN/AN/AGX AcquisitionN/AN/A-$49.26MN/AN/A Do insiders & institutionals believe in MBX or GXGX? 61.7% of GX Acquisition shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend MBX or GXGX? MBX Biosciences currently has a consensus price target of $37.25, indicating a potential upside of 220.02%. Given MBX Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe MBX Biosciences is more favorable than GX Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00GX Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor MBX or GXGX? In the previous week, MBX Biosciences had 2 more articles in the media than GX Acquisition. MarketBeat recorded 2 mentions for MBX Biosciences and 0 mentions for GX Acquisition. MBX Biosciences' average media sentiment score of 0.00 equaled GX Acquisition'saverage media sentiment score. Company Overall Sentiment MBX Biosciences Neutral GX Acquisition Neutral SummaryMBX Biosciences beats GX Acquisition on 7 of the 8 factors compared between the two stocks. Get GX Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for GXGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GXGX vs. The Competition Export to ExcelMetricGX AcquisitionPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$84.09M$6.92B$5.62B$9.14BDividend YieldN/A2.95%5.36%3.98%P/E RatioN/A10.1189.6917.66Price / SalesN/A351.361,219.4081.09Price / CashN/A65.4844.3437.71Price / Book16.715.335.134.73Net Income-$49.26M$157.56M$118.85M$225.42M GX Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GXGXGX AcquisitionN/A$2.34-5.3%N/A+619.5%$84.09MN/A0.00N/AGap DownMBXMBX BiosciencesN/A$9.89-6.2%$37.25+276.6%N/A$330.52MN/A0.0036Gap DownPGENPrecigen3.8303 of 5 stars$1.11flat$6.33+470.6%-12.2%$325.09M$6.22M-2.02190Analyst RevisionOLMAOlema Pharmaceuticals2.2114 of 5 stars$5.66+7.2%$27.00+377.0%-46.6%$324.32MN/A-2.5870CRVSCorvus Pharmaceuticals2.4553 of 5 stars$5.01+5.9%$12.38+147.0%+137.4%$321.93MN/A-5.3930Short Interest ↑Positive NewsCTNMContineum Therapeutics3.2795 of 5 stars$12.44-0.3%$29.25+135.1%N/A$320.68M$50M0.0031Upcoming EarningsNews CoverageCMRXChimerix4.1355 of 5 stars$3.55-3.0%$8.50+139.4%+345.7%$319.29M$320,000.00-3.7890Short Interest ↓News CoverageLFVNLifeVantage4.5067 of 5 stars$25.31+0.0%$30.50+20.5%+275.6%$317.01M$196.01M79.10260Upcoming EarningsXOMAXOMA4.4026 of 5 stars$26.76-1.9%$81.50+204.6%+27.9%$315.23M$4.76M-7.6910Insider TradeTNGXTango Therapeutics3.4238 of 5 stars$2.85+2.5%$13.14+361.2%-74.9%$306.15M$36.53M-2.4290News CoveragePositive NewsTRVITrevi Therapeutics2.5151 of 5 stars$3.76-0.5%$9.31+147.7%+142.8%$289.03MN/A-8.5520Short Interest ↓Gap Up Related Companies and Tools Related Companies MBX Competitors PGEN Competitors OLMA Competitors CRVS Competitors CTNM Competitors CMRX Competitors LFVN Competitors XOMA Competitors TNGX Competitors TRVI Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GXGX) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredTrump’s back in the oval office. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. And he says 2025 could be...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GX Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GX Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
